ASCO 2016 - Lung Cancer
Nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced NSCLC: CheckMate-017/057 2-y update and exploratory cytokine profile analyses
In a 2-year update from CheckMate-017 and CheckMate-063, nivolumab was shown to result in improved overall survival and a favorable safety profile compared with docetaxel in patients with previously treated squamous or nonsquamous non–small-cell lung cancer (NSCLC).
Response to tyrosine kinase inhibitors in advanced non–small-cell lung cancer with concomitant c-MET overexpression and EGFR mutation
Patients with advanced non–small-cell lung cancer with concomitant EGFR mutation and MET overexpression have relatively low response rates with EGFR tyrosine kinase inhibitors (TKIs), indicating that MET overexpression may cause primary resistance to EGFR TKIs, and that this might be overcome by treatment with a combination of EGFR and MET inhibitors.
Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C
In patients with treatment-naive advanced non–small-cell lung cancer (NSCLC), pembrolizumab in combination with standard chemotherapy regimens is feasible and yields substantial clinical efficacy regardless of pembrolizumab dose or PD-L1 status.
A randomized, open label, phase II study comparing pemetrexed plus cisplatin followed by pemetrexed versus pemetrexed alone in EGFR mutant NSCLC patients who have failed first-line EGFR TKI: KCSG-LU12-13
In patients with nonsquamous non–small-cell lung cancer (NSCLC) harboring activating EGFR mutation (del 19 or L858R mutation) who have progressed on first-line EGFR tyrosine kinase inhibitor, patients treated with pemetrexed monotherapy show equivalent progression-free survival compared with those treated with pemetrexed plus cisplatin.
A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study
Bayesian randomized trial comparing intensity-modulated radiation therapy versus passively scattered proton therapy for locally advanced non–small-cell lung cancer
In a Bayesian randomized trial in patients with locally advanced non–small-cell lung cancer, there were no significant differences in treatment failure between patients treated with intensity-modulated radiotherapy and those treated with 3-dimensional proton therapy.
Page 1 of 3
Results 1 - 10 of 24
Results 1 - 10 of 24